This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Hold on to Omnicell (OMCL) Stock Now
by Zacks Equity Research
Investors are optimistic about Omnicell (OMCL) owing to its progress with its three-legged strategic, which is driving growth and an impressive 2025 roadmap.
Omnicell's (OMCL) Automated Dispensing Service Adopted by Aultman
by Zacks Equity Research
Omnicell's (OMCL) Autonomous Pharmacy vision receives another boost with the latest service adoption by Aultman.
Omnicell's (OMCL) 2025 Roadmap Impressive, Pandemic Woe Stays
by Zacks Equity Research
Omnicell (OMCL) expands its autonomous pharmacy portfolio with the acquisition of PSG's 340B Link business.
Omnicell (OMCL) Moves 4.9% Higher: Will This Strength Last?
by Zacks Equity Research
Omnicell (OMCL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Why Is Omnicell (OMCL) Up 0.8% Since Last Earnings Report?
by Zacks Equity Research
Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Omnicell (OMCL) Grows on New Services Amid Pandemic Woes
by Zacks Equity Research
Omnicell (OMCL) is progressing in autonomous pharmacy space by expanding portfolio and investing in the digital cloud-based platform.
Onmicell (OMCL) Q4 Earnings Beat Estimates, Margin Contracts
by Zacks Equity Research
Omnicell's (OMCL) fourth-quarter 2020 revenues rose 0.36% year over year to $249.2 million, improving 16.1% sequentially.
Thermo Fisher (TMO) Q4 Earnings Beat on Growth in All Segments
by Zacks Equity Research
Thermo Fisher (TMO) records $3.2 billion of COVID-19 response revenues and accelerated growth in base business in Q4.
Zacks Industry Outlook Highlights: Omnicell, NextGen Healthcare, NantHealth, Allscripts Healthcare Solutions and Quest Diagnostics
by Zacks Equity Research
Zacks Industry Outlook Highlights: Omnicell, NextGen Healthcare, NantHealth, Allscripts Healthcare Solutions and Quest Diagnostics
Hologic (HOLX) Q1 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Hologic (HOLX) exhibited robust segmental growth in first-quarter fiscal 2021, driven by strong performance by the Diagnostics segment amid the coronavirus pandemic.
3 Top Medical Info Systems Stocks to Beat COVID-19 Resurgence Crisis
by Urmimala Biswas
Despite the severe challenges posed by the COVID-19 pandemic, higher demand for telemedicine, digital influence and AI is likely to lend support to the Zacks Medical - Information industry. OMCL, NXGN and NH are well positioned to gain.
Edwards Lifesciences (EW) Q4 Earnings Fall Shy of Estimates
by Zacks Equity Research
Despite coronavirus-led business challenges, Edwards Lifesciences (EW) witnessed robust performances in TMTT business in Q4.
Abbott (ABT) Q4 Earnings Top, Diagnostic Test Sales Solid
by Zacks Equity Research
Within Diabetes Care, Abbott (ABT) reports strong sales banking on growing demand for sensor-based continuous glucose monitoring system, FreeStyle Libre.
What's in Store for IDEXX Laboratories (IDXX) in Q4 Earnings?
by Zacks Equity Research
IDEXX's (IDXX) fourth-quarter top line is likely to have benefited from strength in CAG and LPD businesses.
Align Technology (ALGN) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Align Technology (ALGN) is expected to have gained from continued recovery in Clear Aligner shipment volumes in Q4.
Omnicell (OMCL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Omnicell (OMCL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Hologic's (HOLX) CE-Marked Fluent System Launched in Europe
by Zacks Equity Research
Hologic (HOLX) aims to optimize, simplify and streamline hysteroscopic workflow with the latest European launch of its fluid management system.
Phreesia (PHR) in Focus: Stock Moves 5.5% Higher
by Zacks Equity Research
Phreesia (PHR) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Can Diagnostics Aid Hologic (HOLX) Q1 Sales Amid Coronavirus?
by Zacks Equity Research
Strength in Molecular Diagnostics business is likely to have continued to aid Hologic's (HOLX) performance in the first quarter of fiscal 2021 amid the coronavirus-led economic doldrums.
What's in Store for Edwards Lifesciences in (EW) Q4 Earnings?
by Zacks Equity Research
Robust customer adoption of the TruWave disposable pressure monitoring devices and INSPIRIS RESILIA aortic valve is likely to have driven Edwards Lifesciences' (EW) Q4 revenues.
Here's Why You Should Add Hologic (HOLX) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Hologic (HOLX) due to a slew of regulatory approvals and buyouts.
Omnicell (OMCL) Reports Encouraging 2020 Preliminary Results
by Zacks Equity Research
Per the preliminary announcement, Omnicell (OMCL) projects 2020 total revenues to surpass its previous guidance.
Looking for a Growth Stock? 3 Reasons Why Omnicell (OMCL) is a Solid Choice
by Zacks Equity Research
Omnicell (OMCL) is well positioned to outperform the market, as it exhibits above-average growth in financials.
NextGen (NXGN) Solution Acts as Financial Bridge Amid COVID-19
by Zacks Equity Research
NextGen's (NXGN) cloud-based EHR platform, NextGen Office, enables specialty practices to improve their financial performance during the pandemic.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH